Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Clinical trial NCT05609630 · RECRUITING

Trial details

NCT number: NCT05609630
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Juvenile Idiopathic Arthritis

Start date: 2023-10-02
Primary completion: 2029-06-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.